SLXN:NASDAQSilexion Therapeutics Corp Analysis
Data as of 2026-05-01 - not real-time
$0.61
Latest Price
9/10Risk
Risk Level: High
Executive Summary
SLXN is trading at $0.61, well below its 20‑day ($0.96), 50‑day ($1.31) and 200‑day ($3.65) simple moving averages, indicating a deep technical weakness. The 14‑day RSI of 20.7 signals oversold conditions, while the MACD histogram remains negative, confirming a bearish momentum. Yet the stock sits just above its calculated support of $0.473 and faces resistance near $1.26, suggesting a potential bounce zone.
Fundamentally, the company has zero revenue, negative EBITDA of $‑11.6 M, and a cash balance of $5.99 M offset by $2.04 M debt, leading to a high debt‑to‑equity of 78% and a max drawdown of ‑96%. Analysts rate the stock as a strong buy with a consensus target of $6, implying an 880% upside, and the market sentiment index reads “Extreme Greed” at 90.9, highlighting speculative enthusiasm despite the high volatility (100% 30‑day) and beta of 2.28.
Fundamentally, the company has zero revenue, negative EBITDA of $‑11.6 M, and a cash balance of $5.99 M offset by $2.04 M debt, leading to a high debt‑to‑equity of 78% and a max drawdown of ‑96%. Analysts rate the stock as a strong buy with a consensus target of $6, implying an 880% upside, and the market sentiment index reads “Extreme Greed” at 90.9, highlighting speculative enthusiasm despite the high volatility (100% 30‑day) and beta of 2.28.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Oversold RSI suggests near‑term price floor
- Support level at $0.473 provides downside cushion
- Extreme market greed may drive short‑term buying pressure
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Analyst consensus strong‑buy with $6 target
- Pipeline potential of LODER platform
- High upside potential (≈880%) outweighs current cash‑flow deficits
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Biotech growth narrative and unmet oncology market
- Strategic collaboration with Evonik for siRNA formulation
- Long‑term valuation gap relative to industry peers
Key Metrics & Analysis
Financial Health
P/E Ratio-1.0
ROA-144.28%
Debt/Equity78.22
P/B Ratio0.7
Op. Cash Flow$-10819000
Free Cash Flow$-6507125
Industry P/E25.7
Technical Analysis
TrendBearish
RSI20.7
Support$0.47
Resistance$1.26
MA 20$0.96
MA 50$1.31
MA 200$3.65
MACDBearish
VolumeStable
Fear & Greed Index90.91
Valuation
Target Price$6.00
Upside/Downside880.23%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta2.28
Volatility100.09%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.